Smith Chas P & Associates PA Cpas Sells Amgen Shares

Firm reduces stake in medical research company by 40.7% in third quarter

Published on Mar. 4, 2026

Got story updates? Submit your updates here. ›

Smith Chas P & Associates PA Cpas, an investment firm, trimmed its position in shares of Amgen Inc. (NASDAQ:AMGN) by 40.7% during the third quarter, according to a recent SEC filing. The firm now owns 69,274 shares of the medical research company's stock, down from 116,729 shares previously.

Why it matters

Amgen is a major biopharmaceutical company that develops and markets a variety of drugs and therapies. Changes in institutional ownership of its stock can signal shifts in investor sentiment and market trends around the company.

The details

According to the SEC filing, Smith Chas P & Associates PA Cpas sold 47,455 shares of Amgen stock during the third quarter. The firm's remaining stake in Amgen is now valued at $19,549,000, accounting for approximately 1.7% of its overall portfolio.

  • The share sale occurred during the third quarter of 2026.

The players

Smith Chas P & Associates PA Cpas

An investment firm that manages a portfolio of stocks, including a significant position in Amgen.

Amgen Inc.

A global biotechnology company that focuses on discovering, developing, manufacturing, and delivering human therapeutics to address serious illnesses.

Got photos? Submit your photos here. ›

The takeaway

The reduction in Smith Chas P & Associates PA Cpas' Amgen holdings may reflect a broader shift in investor sentiment around the stock, though the reasons behind the firm's decision are not explicitly stated. Investors will likely continue to monitor changes in institutional ownership of Amgen as an indicator of market trends and sentiment around the company.